The tweet was deleted by the author.
But we saved everything 🙂.
Greenwich LifeSciences has presented preliminary data from its FLAMINGO-01 open label study at the AACR Meeting 2026.
The early-stage results signal continued progress in the company's ongoing research and development efforts for its investigational therapies. Details from the study underscore a focus on innovation in cancer treatment. Investors and medical professionals are closely monitoring the findings as the study advances.
Greenwich LifeSciences recently moved to secure new patent claims following data from the FLAMINGO-01 study showing a statistically significant immune response. The company has also provided a strategic update on its financing approach as it navigates current market dynamics. These developments come as research results attract investor and clinical attention.